NEW YORK, Oct. 23 - Incyte Genomics and Genentech have struck a licensing deal that covers patents covering therapeutic antibodies to four proteins discovered by Incyte, the companies said on Tuesday.

Under terms of the agreement, Incyte is entitled to receive clinical development milestone payments for the antibodies and royalties if any are commercialized.

Financial terms of the agreement and the intended clinical uses of the four antibodies were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.